You are here

Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain

Last updated on May 10, 2018

FOR MORE INFORMATION
Study Location
Avail Clinical Research, LLC
Deland, Florida, 32720 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Chronic Noncancer Pain
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subject has moderate to severe chronic noncancer pain (duration of at least 3 months)
requiring a continuous around-the-clock opioid analgesic for an extended period of
time. Conditions may include, but are not limited to, osteoarthritis, chronic low back
pain, or other opioid -responsive pain conditions.

- Subject agrees to refrain from taking opioid medications other than study drug during
the study. (The exception is during the Pre-Treatment Period when the subject may
continue current opioid therapy to guide first 4 weeks of the Treatment Period when
the subject may administer immediate-release oxycodone to support conversion to study
drug.)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subject has moderate or severe chronic pain due to cancer, migraine, recent trauma,
infection, or other pain expected to be short-term (duration less than 3 months).

- Subject has a documented history of alcohol or drug abuse within 1 year prior to study
entry that in the Investigator's judgment would impact subject participation.

- Subject has ongoing or active alcohol or drug abuse that in the Investigator's
judgment would impact subject participation.

- Subject has a positive urine drug test for illicit drug use or medications at
screening without legitimate medical explanation.

- Subject has a clinically significant medical condition (e.g., cardiovascular,
neurological, renal, hepatic, pulmonary, gastrointestinal, endocrine, hematological,
immunological, rheumatological, metabolic, or psychiatric) or physical examination,
vital signs (VS), 12-lead electrocardiogram (ECG), clinical laboratory abnormalities
that in the opinion of the Investigator would impact the safety of the subject during
study participation.

- If female, the subject is pregnant or breast-feeding.

- Subject has a known history or known hypersensitivity to oxycodone, oxycodone salts,
naltrexone or acetaminophen,or pharmacological similar compounds.

- Subject is historically non-responsive to oxycodone treatment or requires greater than
160 mg oxycodone in a 24-hour time interval.

NCT01428583
Pfizer
Completed
Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain
A Multicenter, 12-month, Open-label, Single-arm, Safety Study Of Oxycodone Hydrochloride And Naltrexone Hydrochloride Extended-release Capsules In Subjects With Moderate To Severe Chronic Noncancer Pain
The study will provide information to assess the benefits versus risks of extended exposure to oxycodone HCl and naltrexone HCl extended-release capsules in a chronic noncancer pain population.
Not Provided
Interventional
Phase 3
Masking: None (Open Label)
Primary Purpose: Supportive Care
Chronic Noncancer Pain
Drug: oxycodone HCl and naltrexone HCl extended-release capsules
Daily dose range of 20 mg to 160 mg of the oxycodone component in a 24 hour time interval, administered twice daily approximately 12 hours apart (At the discretion of the Investigator, oxycodone HCl and naltrexone HCl extended-release capsules may be administered once daily, at 24 hour intervals.)
Other Name: ALO-02
Experimental: oxycodone HCl and naltrexone HCl extended-release capsules
Intervention: Drug: oxycodone HCl and naltrexone HCl extended-release capsules
Arora S, Setnik B, Michael D, Hudson JD, Clemmer R, Meisner P, Pixton GC, Goli V, Sommerville KW. A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic noncancer pain. J Opioid Manag. 2014 Nov-Dec;10(6):423-36. doi: 10.5055/jom.2014.0239.


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
395
May 2012
May 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject has moderate to severe chronic noncancer pain (duration of at least 3 months) requiring a continuous around-the-clock opioid analgesic for an extended period of time. Conditions may include, but are not limited to, osteoarthritis, chronic low back pain, or other opioid -responsive pain conditions.
  • Subject agrees to refrain from taking opioid medications other than study drug during the study. (The exception is during the Pre-Treatment Period when the subject may continue current opioid therapy to guide first 4 weeks of the Treatment Period when the subject may administer immediate-release oxycodone to support conversion to study drug.)

Exclusion Criteria:

  • Subject has moderate or severe chronic pain due to cancer, migraine, recent trauma, infection, or other pain expected to be short-term (duration less than 3 months).
  • Subject has a documented history of alcohol or drug abuse within 1 year prior to study entry that in the Investigator's judgment would impact subject participation.
  • Subject has ongoing or active alcohol or drug abuse that in the Investigator's judgment would impact subject participation.
  • Subject has a positive urine drug test for illicit drug use or medications at screening without legitimate medical explanation.
  • Subject has a clinically significant medical condition (e.g., cardiovascular, neurological, renal, hepatic, pulmonary, gastrointestinal, endocrine, hematological, immunological, rheumatological, metabolic, or psychiatric) or physical examination, vital signs (VS), 12-lead electrocardiogram (ECG), clinical laboratory abnormalities that in the opinion of the Investigator would impact the safety of the subject during study participation.
  • If female, the subject is pregnant or breast-feeding.
  • Subject has a known history or known hypersensitivity to oxycodone, oxycodone salts, naltrexone or acetaminophen,or pharmacological similar compounds.
  • Subject is historically non-responsive to oxycodone treatment or requires greater than 160 mg oxycodone in a 24-hour time interval.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01428583
ALO-02-10-3001
B4531001 ( Other Identifier: Alias Study Number )
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
June 2016

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now